Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part 1 Assessing and utilizing the diagnostic or prognostic power of biomarkers
- Part 2 Biomarkers of kidney disease and dysfunction
- Part 3 Biomarkers of bone disease and dysfunction
- Part 4 Biomarkers of liver disease and dysfunction
- 15 Biomarkers of hepatic disease
- 16 The immunogenetics of metabolic liver disease
- 17 Toxicogenetic markers of liver dysfunction
- 18 Prognosis and management of patients with acute liver failure
- 19 Biomarkers in artificial and bioartificial liver support
- 20 Prognostic markers in liver disease
- 21 Apoptosis: biomarkers and the key role of mitochondria
- 22 Liver regeneration: mechanisms and markers
- 23 Determinants of responses to viruses and self in liver disease
- 24 IL-6-type cytokines and signalling in inflammation
- Part 5 Biomarkers of gastrointestinal disease and dysfunction
- Part 6 Biomarkers in toxicology
- Part 7 Biomarkers of cardiovascular disease and dysfunction
- Part 8 Biomarkers of neurological disease and dysfunction
- Part 9 Biomarkers in transplantation
- Index
22 - Liver regeneration: mechanisms and markers
Published online by Cambridge University Press: 20 August 2009
- Frontmatter
- Contents
- List of contributors
- Preface
- Part 1 Assessing and utilizing the diagnostic or prognostic power of biomarkers
- Part 2 Biomarkers of kidney disease and dysfunction
- Part 3 Biomarkers of bone disease and dysfunction
- Part 4 Biomarkers of liver disease and dysfunction
- 15 Biomarkers of hepatic disease
- 16 The immunogenetics of metabolic liver disease
- 17 Toxicogenetic markers of liver dysfunction
- 18 Prognosis and management of patients with acute liver failure
- 19 Biomarkers in artificial and bioartificial liver support
- 20 Prognostic markers in liver disease
- 21 Apoptosis: biomarkers and the key role of mitochondria
- 22 Liver regeneration: mechanisms and markers
- 23 Determinants of responses to viruses and self in liver disease
- 24 IL-6-type cytokines and signalling in inflammation
- Part 5 Biomarkers of gastrointestinal disease and dysfunction
- Part 6 Biomarkers in toxicology
- Part 7 Biomarkers of cardiovascular disease and dysfunction
- Part 8 Biomarkers of neurological disease and dysfunction
- Part 9 Biomarkers in transplantation
- Index
Summary
Introduction
During liver regeneration, quiescent differentiated hepatocytes replicate to restore hepatic tissue. Regeneration can be triggered by the surgical removal of liver tissue or by hepatocyte loss caused by chemical or viral injury. Regardless of the cause, hepatocytes proliferate in a relatively synchronous way to restore the functional capacity of the liver. The most extensively studied model of liver regeneration is that which occurs after removal of two-thirds of the liver (partial hepatectomy). Remarkably, this process, which is referred to as ‘regeneration’, does not involve true regenerative growth [1]; the hepatic lobes removed by the operation do not grow back. Instead, hepatic mass increases by compensatory hyperplasia of the remaining lobes. These lobes increase in size as a consequence of hepatocyte proliferation and the process terminates when the mass of the enlarged lobes reaches that of the original liver. This chapter will highlight the precise regulatory controls which are activated during this remarkable growth process and identify those key components that may be considered as candidate biomarkers of regeneration. In rodents, 90–95% of hepatocytes replicate within 2 days after partial hepatectomy. DNA replication is preceded by a prereplicative phase in which a large number of genes are activated [2].
Experimental and clinical features
Liver regeneration is important both from a scientific perspective and clinically. The same growth factors that regulate liver regeneration in rodents also appear to be active in humans.
- Type
- Chapter
- Information
- Biomarkers of DiseaseAn Evidence-Based Approach, pp. 239 - 243Publisher: Cambridge University PressPrint publication year: 2002